Biotech Values

[DewDiligence]

IDIX – In #msg-34894217 I was clearly referring to the gross up-front cash, not the portion of it excluding equity:

$25M would make the arithmetic in #msg-34813718 work—barely. Hence, I think it’s reasonable to consider $25M a lower bound for the up-front amount.

At $6.87/sh, the $17M of new equity from the GSK deal translates into 2.47M new shares, which is roughly a 4% expansion in the shares outstanding. I’m OK with that.